SI3087085T1 - Sinteza tripeptida, ki zavira makrociklični NS3HCV - Google Patents

Sinteza tripeptida, ki zavira makrociklični NS3HCV

Info

Publication number
SI3087085T1
SI3087085T1 SI201431166T SI201431166T SI3087085T1 SI 3087085 T1 SI3087085 T1 SI 3087085T1 SI 201431166 T SI201431166 T SI 201431166T SI 201431166 T SI201431166 T SI 201431166T SI 3087085 T1 SI3087085 T1 SI 3087085T1
Authority
SI
Slovenia
Prior art keywords
synthesis
macrocyclic hcv
tripeptide
inhibiting
inhibiting tripeptide
Prior art date
Application number
SI201431166T
Other languages
English (en)
Slovenian (sl)
Inventor
Amy Cagulada
Johann Chan
Lina Chan
Denise A. Colby
Kapil Kumar Karki
Darryl Kato
Katie Ann Keaton
Sudha Kondapally
Chris Levins
Adam Littke
Ruben Martinez
Dominika Pcion
Troy Reynolds
Bruce Ross
Michael Sangi
Adam J. Schrier
Pamela Seng
Dustin Siegel
Nathan Shapiro
Donald Tang
James G. Taylor
Jonathan Tripp
Lawrence Yu
Andrew W. Waltman
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of SI3087085T1 publication Critical patent/SI3087085T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/02Formation of carboxyl groups in compounds containing amino groups, e.g. by oxidation of amino alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/12Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton being acyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/61Carboxylic acid nitriles containing cyano groups and nitrogen atoms being part of imino groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/32Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40Benzopyrazines
    • C07D241/44Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
SI201431166T 2013-12-23 2014-12-18 Sinteza tripeptida, ki zavira makrociklični NS3HCV SI3087085T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920446P 2013-12-23 2013-12-23
PCT/US2014/071319 WO2015100145A1 (en) 2013-12-23 2014-12-18 Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide
EP14822040.3A EP3087085B1 (en) 2013-12-23 2014-12-18 Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide

Publications (1)

Publication Number Publication Date
SI3087085T1 true SI3087085T1 (sl) 2019-05-31

Family

ID=52278856

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431166T SI3087085T1 (sl) 2013-12-23 2014-12-18 Sinteza tripeptida, ki zavira makrociklični NS3HCV

Country Status (20)

Country Link
US (2) US9440991B2 (enExample)
EP (1) EP3087085B1 (enExample)
JP (1) JP6425727B2 (enExample)
KR (1) KR102366697B1 (enExample)
CN (3) CN105849118B (enExample)
AR (1) AR098959A1 (enExample)
AU (1) AU2014370125B2 (enExample)
CA (1) CA2934537C (enExample)
EA (1) EA201691031A1 (enExample)
ES (1) ES2724460T3 (enExample)
IL (1) IL246064A0 (enExample)
MX (1) MX2016008452A (enExample)
NZ (1) NZ720745A (enExample)
PL (1) PL3087085T3 (enExample)
PT (1) PT3087085T (enExample)
SG (1) SG11201604482QA (enExample)
SI (1) SI3087085T1 (enExample)
TR (1) TR201906413T4 (enExample)
TW (3) TWI762003B (enExample)
WO (1) WO2015100145A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9809576B1 (en) 2014-07-18 2017-11-07 Abbvie Inc. Synthetic route to anti-viral agents
US9809534B1 (en) * 2014-07-21 2017-11-07 Abbvie Inc. Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en) 2015-01-30 2019-06-11 Abb Vie Inc. Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
US10450291B2 (en) 2015-06-29 2019-10-22 Central Glass Company, Limited Method for producing fluorine-containing cyclopropane carboxylic acid compound
JP2020505952A (ja) 2017-02-01 2020-02-27 アッヴィ・インコーポレイテッド (±)−2−(ジフルオロメチル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸及び(±)−2−(ビニル)−1−(アルコキシカルボニル)シクロプロパンカルボン酸の酵素的製造方法
WO2019084740A1 (zh) * 2017-10-31 2019-05-09 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) * 2017-10-31 2018-02-27 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107827748A (zh) * 2017-11-14 2018-03-23 安徽华胜医药科技有限公司 一种乙酸2‑烯丙基环丙酯消旋体的合成方法
KR102519417B1 (ko) 2018-11-28 2023-04-10 삼성디스플레이 주식회사 스트레처블 표시 장치
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
CN116041181A (zh) * 2023-01-04 2023-05-02 广州巨元生化有限公司 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006125446A (ru) * 2003-12-15 2008-01-27 Джапан Тобакко Инк. (Jp) Производные n-замещенного n-сульфониламиноциклопропана и их фармацевтическое применение
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8211891B2 (en) 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
EP2540349B1 (en) * 2008-07-22 2014-02-12 Merck Sharp & Dohme Corp. Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2289880A1 (en) * 2009-07-08 2011-03-02 Bayer CropScience AG 2-Pyridinylcyclopropylbenzamide fungicides
SG188618A1 (en) * 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
AR084217A1 (es) * 2010-12-10 2013-05-02 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2015095430A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
AU2014370125B2 (en) 2013-12-23 2017-11-16 Gilead Sciences, Inc. Synthesis of a macrocyclic HCV NS3 inhibiting tripeptide
ES2708993T3 (es) * 2013-12-23 2019-04-12 Gilead Sciences Inc Formas cristalinas de un tripéptido macrocíclico inhibidor de NS3 del VHC

Also Published As

Publication number Publication date
CN105849118B (zh) 2020-03-31
HK1222401A1 (zh) 2017-06-30
CA2934537A1 (en) 2015-07-02
TW201609711A (zh) 2016-03-16
TWI762003B (zh) 2022-04-21
CN116813596A (zh) 2023-09-29
KR102366697B1 (ko) 2022-02-25
AU2014370125A1 (en) 2016-06-23
JP6425727B2 (ja) 2018-11-21
US20170210756A1 (en) 2017-07-27
AU2014370125B2 (en) 2017-11-16
TWI671292B (zh) 2019-09-11
TWI710547B (zh) 2020-11-21
CA2934537C (en) 2022-08-16
US9440991B2 (en) 2016-09-13
EP3087085A1 (en) 2016-11-02
IL246064A0 (en) 2016-07-31
MX2016008452A (es) 2016-10-14
KR20160101934A (ko) 2016-08-26
CN111320610A (zh) 2020-06-23
US10030033B2 (en) 2018-07-24
JP2017509585A (ja) 2017-04-06
SG11201604482QA (en) 2016-07-28
NZ720745A (en) 2018-02-23
CN111320610B (zh) 2023-06-06
US20150175626A1 (en) 2015-06-25
EP3087085B1 (en) 2019-02-20
TR201906413T4 (tr) 2019-05-21
WO2015100145A1 (en) 2015-07-02
PL3087085T3 (pl) 2019-07-31
ES2724460T3 (es) 2019-09-11
TW202106661A (zh) 2021-02-16
TW201938527A (zh) 2019-10-01
EA201691031A1 (ru) 2017-01-30
AR098959A1 (es) 2016-06-22
CN105849118A (zh) 2016-08-10
PT3087085T (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
IL246064A0 (en) Preparation of a macrocyclic tripeptide inhibiting hcv ns3
PL2850085T3 (pl) Antywirusowe związki inhibitorowe hcv ns5a
HUS1700039I1 (hu) Makrociklusos prolinból leszármaztatható HCV szerin proteáz inhibitorok
EP2575866A4 (en) HCV NS5A INHIBITORS
EP2575475A4 (en) HCV NS5A INHIBITORS
GB201421334D0 (en) Synthesis of aeizeolite
PL2858493T3 (pl) Synteza MOF
EP2802574A4 (en) INHIBITORS OF HCV NS3 PROTEASE
IL239172A0 (en) Methods for the synthesis of a prostacyclin analog
IL227642A0 (en) Rifaximin formulations and their uses
IL225908A0 (en) New specific inhibitors for 3ns hcv protease
PT3087086T (pt) Formas cristalinas de um tripéptido inibidor de hcv ns3 macrocíclico
ZA201401986B (en) Hcv immunotherapy
IL241042A0 (en) Methods for the synthesis of a difluorolactam analog
IL237049A0 (en) Combination of HCV macrocyclic tertase inhibitor, non-nucleoside HCV inhibitor and ritonavir
PT3024835T (pt) Nova síntese de noroximorfona a partir de morfina
HK40095381A (zh) 大环hcv ns3抑制三肽的合成
IL233550A0 (en) Stable pharmaceutical formulations of an effective hepatitis c virus inhibitor
PL2984237T3 (pl) Nadmuchiwany odbijacz
HK1230215A1 (en) Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
GB201320732D0 (en) Methods of chemical synthesis
GB2501060B (en) Cover for pipe bag of bagpipes
GB201201456D0 (en) Flexible scarf
GB201113600D0 (en) Leg tether
TWM488989U (en) Multi-purpose epidemic prevention health-caring belt